Surgery

The FDA 510(k) clearance K040187 (June 21, 2004; Ricarimpex SAS) specifies two indications: (1) removing pooled blood beneath skin grafts to facilitate healing, and (2) restoring circulation in blocked veins through blood removal. A second supplier — Biopharm (UK) Ltd. — received 510(k) clearance K132958 in 2014. Both suppliers distribute Hirudo verbana (taxonomically confirmed by Siddall et al., 2007, Proc R Soc B), which falls under the same FDA product code (NRN) as Hirudo medicinalis.

On December 30, 2024, the FDA transferred regulatory responsibility for medicinal leeches from the Center for Devices and Radiological Health (CDRH) to the Center for Biologics Evaluation and Research (CBER). This administrative transfer does not affect clinical use or availability.

The aggregate evidence across four systematic reviews demonstrates a consistent salvage rate of 75-84% for venous-congested tissue transfers. The mechanism is unique and irreplaceable: active blood extraction by the leech (5-15 mL per feeding); pharmacologic anticoagulation via hirudin (direct thrombin inhibition), calin/saratin (platelet aggregation inhibition), and factor Xa inhibitors; and sustained post-detachment bleeding lasting 4 to 24 hours, providing continued venous decompression after the leech detaches. No synthetic device or pharmaceutical replicates this combination.

Venous congestion is the most common cause of flap failure, responsible for approximately 80% of all flap losses. When the venous pedicle is thrombosed or the venous anastomosis is compromised, the flap develops progressive edema, cyanosis, and capillary refill failure. Without intervention, ischemic necrosis follows within hours. Medicinal leech therapy addresses this emergency through three concurrent mechanisms:

Digit replantation, particularly of distal fingertips where veins are too small for microsurgical anastomosis (typically distal to the DIP joint), represents one of the most established applications of medicinal leech therapy. The distal digital venous system is too fine for reliable microvascular repair — arterial inflow can be re-established, but venous outflow cannot. Without venous decompression, the replanted digit develops progressive congestion and necrosis. Medicinal leeches provide the only effective bridge to neovascularization (typically 5-7 days).

A critical clinical question: should leeches be applied prophylactically (immediately after replantation, before clinical congestion develops) or reactively (only when congestion signs appear)? Retrospective data from 25 distal digit replantations shows a dramatic advantage for the prophylactic approach:

Ear replantation presents a unique microsurgical challenge: the external ear has a limited number of veins, and venous anastomosis is frequently impossible — particularly in crush or avulsion injuries where venous structures are destroyed. For decades, this made total ear replantation technically possible but clinically unreliable. The introduction of medicinal leech therapy transformed this situation by providing a reliable alternative venous outflow pathway.

The cumulative published experience of over 84 cases demonstrates an approximately 80% salvage rate for ear replantation with leech therapy — a remarkable outcome for a procedure that was previously considered futile when venous repair was impossible. The key insight: artery-only replantation (arterial inflow without venous outflow) is viable when leeches provide bridge venous decompression until neovascularization establishes new venous channels (typically 5-7 days).

Breast reconstruction using autologous tissue transfer (TRAM and DIEP flaps) carries a significant risk of venous congestion due to the large tissue volume and the technical demands of microsurgical pedicle dissection. Smolle et al. (2024) systematically reviewed 28 cases and reported a 75% salvage rate with leech therapy — lower than the 78% rate reported for non-breast flaps. The complication rate was notably high at 81.14%, reflecting the greater blood loss associated with decompressing large-volume tissue transfers.

The disparity between breast flap outcomes and other tissue transfers reflects fundamental biology: larger flaps have more tissue volume requiring decompression, longer treatment courses, greater transfusion requirements, and higher infection risk due to prolonged leech contact. Nguyen et al. (2012) documented that regional and free flaps achieved only 33.3% salvage with leech therapy, compared to 100% for native and local tissue — though this difference likely reflects the severity of the underlying vascular compromise rather than treatment failure.

Head and neck reconstruction after malignant tumor resection frequently requires free tissue transfer to restore function and form. Seleznev (1998) reported the largest published series of leech therapy in this context: 98 patients with postoperative defects of the pharynx and esophagus following tumor removal. Preoperative leech therapy restored tissue oxygen content in 69.9% and achieved partial restoration in 30.2%. Postoperatively, leech therapy contributed to transplant viability in all cases, with functional outcomes improving 26.2-48.4% compared with controls.

Tissue transfers to burn wound beds face heightened risk of venous congestion due to scarred, fibrotic, and poorly vascularized recipient tissue. The anti-inflammatory properties of leech SGS (bdellins, eglins, complement inhibitors) may provide additional benefit in the chronic inflammatory milieu of burn scars. Although no dedicated clinical study has examined leech therapy specifically for burn reconstruction, the mechanism of action — local venous decompression with anti-inflammatory modulation — applies directly to this context.

Keloids remain one of the most frustrating problems in plastic surgery, with recurrence rates of 45-100% after excision alone and 10-50% even with adjuvant therapy (corticosteroid injection, radiation, pressure therapy, silicone sheeting). Two properties of leech SGS suggest a potential role in keloid management: destabilase-mediated fibrinolytic activity (which may help degrade excessive fibrin and collagen cross-links in the extracellular matrix) and anti-inflammatory effects (which may modulate the chronic inflammatory state that drives keloid formation through TGF-beta-mediated fibroblast activation).

Sulim and Volokitin (2003) observed scar softening and increased elasticity in 83% of 18 patients with gunshot wound scars following leech therapy. While gunshot scars differ pathophysiologically from keloids, the underlying mechanism — improved microcirculation with consequent tissue remodeling — is analogous. Clinical evidence for keloid-specific application remains preliminary, and controlled studies comparing leech therapy to established keloid treatments are needed.

Thrombophlebitis is the longest-documented surgical indication for leech therapy, with systematic reports dating to Ternier (1922). The evidence base includes two controlled studies: Kutakov (1965, n=80 including 60 patients and 20 animals) demonstrated efficacy in subacute but not chronic thrombophlebitis; Magomedov (1998, n=46) showed a 43% reduction in hospital length of stay (11.1 vs 19.5 days) with leech therapy versus standard care — the strongest comparative evidence for any general vascular application.

The biological rationale is multifactorial: local bloodletting reduces venous hypertension in the affected segment; SGS anticoagulants (hirudin, calin, factor Xa inhibitors) prevent thrombus propagation; destabilase provides thrombolytic activity against stabilized fibrin; and anti-inflammatory components mitigate the perivenous inflammation that characterizes thrombophlebitis. The treatment protocol involves placement of 4-6 leeches along the course of the inflamed vein, proximal to the thrombus head, with sessions every 2-3 days for 3-5 sessions.

Chronic venous insufficiency (CVI) affects an estimated 25-33% of women and 10-20% of men in Western populations (Rabe et al., 2012, Vein Consult Program — 91,545 patients across 20 countries). The spectrum ranges from cosmetically concerning telangiectases to debilitating venous ulcers. Leech therapy has been used for CVI for centuries, with the modern evidence base consisting primarily of case series.

Musina and Baybulatova (1998) documented outcomes in 38 patients with post-sclerotherapy complications: application of 8-10 leeches along the indurated vein resulted in resolution of induration, pain, and swelling in all patients. Bapat et al. (1998) reported 100% ulcer healing in 20 patients with chronic varicose ulcers. Shchekotov (1980) described favorable outcomes in 67 patients with chronic venous ulcers of venous etiology. While these results are encouraging, no randomized controlled trials compare leech therapy to compression therapy, surgical correction, or modern endovenous ablation for CVI.

Post-thrombotic syndrome (PTS) develops in 20-50% of patients after deep vein thrombosis, causing chronic leg pain, swelling, skin changes, and in severe cases, venous ulceration (Kahn et al., 2014, Circulation). Eldor et al. (1998) reported the largest series: 87 patients with PTS treated with leech therapy, with favorable outcomes in symptom reduction. The proposed mechanism includes improved microcirculation in post-phlebitic tissue, anti-inflammatory effects on the chronic inflammatory state of PTS, and destabilase-mediated dissolution of residual thrombus.

Several investigators have documented leech therapy for postoperative wound complications and chronic soft tissue injuries. Zimin (1998) conducted the strongest study: a controlled trial of 59 patients with postoperative suppurative wounds following abdominal surgery, demonstrating a 37% relative risk reduction in wound complications (8.4% vs 13.3%) with perioperative leech therapy. Nechaev and Lesovnikova (2001) reported positive outcomes in 43 patients with chronic post-traumatic soft tissue injuries affecting tendons, ligaments, and fasciae. Sulim (1997) documented complete pain elimination in 27 patients with post-traumatic stump pain and phantom limb symptoms.

Developed following the multidrug-resistant case reported in 2020 (IDCases), this protocol represents current best practice for institutions performing leech therapy:

The implementation of leech therapy in US hospitals has matured from ad hoc bedside application to standardized, protocol-driven care. An estimated 100,000 medicinal leeches are supplied to US hospitals annually (~80,000 from Ricarimpex SAS, France; ~20,000 from Biopharm UK via Carolina Biological Supply Company), at a cost of approximately $10-15 per leech.

A 2022 cost-effectiveness analysis modeled leech therapy duration thresholds for digit replantation against the widely accepted $100,000/QALY willingness-to-pay benchmark. At the time of the study, per-unit leech acquisition cost from FDA-cleared suppliers was approximately $10–15. However, current market pricing — inclusive of shipping, cold-chain handling, and regulatory compliance — has risen to approximately $25–30 per leech, reflecting broader supply-chain pressures and limited domestic availability. A standard clinical course requires 30–160+ leeches depending on the severity of venous congestion, translating to direct biologic costs of $750–$4,800 per patient at 2025 market rates. Total episode-of-care costs (including nursing labor for leech management, transfusion support, antibiotic prophylaxis, and extended inpatient stay) ranged from $12,622 to $123,563 in the original analysis; current figures are likely higher.

The use of a living organism as a medical device introduces unique patient-interaction considerations. Patient cooperation directly affects treatment success — an anxious, non-cooperative patient makes leech application more difficult and may inadvertently dislodge feeding leeches. Pre-treatment education by nursing staff significantly improves tolerance.

Hirudin, the leech's signature 65-amino-acid thrombin inhibitor, has directly inspired an entire class of FDA-approved anticoagulants. The trajectory from natural product to pharmaceutical agent represents one of the most successful natural-product-to-pharmaceutical translations in modern medicine — culminating in a drug with a Class I ACC/AHA recommendation and a nearly $1 billion market.

The American Society of Hirudotherapy supports the continued development of evidence-based surgical applications of medicinal leech therapy. Priority research areas include: